Observational studyTransfusion2019
Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study.
Observational study in Transfusion, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Trial
- Heart rate changes after phlebotomy in polycythaemia vera and healthy donors: An observational case-crossover pilot study.Transfusion medicine (Oxford, England) · 2026Observational
- Physiological determinants and the red blood cells transfusion decision-making process in non-bleeding critically ill patients: a comprehensive narrative review.Intensive care medicine · 2026Review
- Cost-effectiveness of a hypothetical assay to evaluate stored blood quality prior to transfusion.Vox sanguinis · 2026Article
- Patient characteristics and clinical determinants of outpatient red cell transfusions.Transfusion · 2025Article
- Transfusion thresholds: the need for a patient-centered approach in hematologic disorders that require chronic transfusion therapy.Blood research · 2023Review
- Hemoglobin modulation affects physiology and patient reported outcomes in anemic and non-anemic subjects: An umbrella review.Frontiers in physiology · 2023Review
- Targeting Stress Erythropoiesis Pathways in Cancer.Frontiers in physiology · 2022Review
- Management of the Older Patient with Myelodysplastic Syndrome.Drugs & aging · 2021Review
- Outpatient transfusions for myelodysplastic syndromes.Hematology. American Society of Hematology. Education Program · 2020Review
- The effect of red blood cell transfusion on fatigability after hospital discharge.Blood advances · 2020Observational
- Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Article
- Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
Corrections and comments
- Commented on by
Authors and funding
21 authors at 10 institutions in 2 countries.
Funding
Abstract
backgroundPatients with cancer or other diagnoses associated with chronic anemia often receive red blood cell (RBC) transfusion as outpatients, but the effect of transfusion on functional status is not well demonstrated. STUDY DESIGN AND
methodsTo estimate the effect of transfusion on functional status and quality of life, we measured 6-minute walk test distance and fatigue- and dyspnea-related quality-of-life scores before and 1 week after RBC transfusion in 208 outpatients age ≥50 with at least one benign or malignant hematology/oncology diagnosis. To account for potential confounding effects of cancer treatment, patients were classified into two groups based on cancer treatment within 4 weeks of the study transfusion. Minimum clinically important improvements over baseline were 20 meters in walk test distance, 3 points in fatigue score, and 2 points in dyspnea score.
resultsThe median improvement in unadjusted walk test distance was 20 meters overall and 30 meters in patients not receiving recent cancer treatment. Fatigue scores improved overall by a median of 3 points and by 4 points in patients without cancer treatment. There was no clinically important change in dyspnea scores. In multiple linear regression analysis, patients who maintained hemoglobin (Hb) levels of 8 g/dL or greater at 1 week posttransfusion, who had not received recent cancer treatment, and who did not require hospitalization during the study showed clinically important increases in mean walk test distance.
conclusionsRed blood cell transfusion is associated with a modest, but clinically important improvement in walk test distance and fatigue score outcomes in adult hematology/oncology outpatients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.